Clinical Scorecard: Intense Pulsed Light for Dry Eye
At a Glance
| Category | Detail |
|---|---|
| Condition | Dry Eye Disease (DED) |
| Key Mechanisms | Improves tear film stability, meibomian gland performance, and modulates ocular surface inflammation. |
| Target Population | Patients with meibomian gland dysfunction (MGD) and diagnosed with DED. |
| Care Setting | Clinical settings offering IPL therapy. |
Key Highlights
- Three IPL sessions outperform two in improving tear film stability and meibomian gland function.
- NITBUT increased significantly from ~4.8 seconds to over 8 seconds in the three-session group.
- Significant rise in lymphotoxin-alpha (LT-α) levels only in the three-session regimen, indicating immune modulation.
Guideline-Based Recommendations
Diagnosis
- Use TFOS DEWS II criteria for diagnosing DED.
Management
- Consider three IPL sessions for optimal outcomes in patients with MGD.
Monitoring & Follow-up
- Assess NITBUT, meibomian gland scores, and OSDI scores at baseline and follow-up.
Risks
- Monitor for potential plateau in patient-perceived benefits despite ongoing objective improvements.
Patient & Prescribing Data
Patients diagnosed with DED and MGD.
IPL therapy is a biologically active treatment that may restore immune homeostasis.
Clinical Best Practices
- Implement a three-session IPL regimen for enhanced therapeutic effect.
- Evaluate both subjective and objective measures of improvement in DED.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
